Cellectar Biosciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Cellectar Biosciences generated cash of -$32,376,974, which is less than the previous year. Cash used in financing activities reached the amount of $22,939,642 last year. Net change in cash is therefore -$10,301,370.
Cash Flow
| 2014 | -8.84M | -29.56K | 15.87M |
|---|---|---|---|
| 2015 | -8.21M | -58.47K | 2.70M |
| 2016 | -8.28M | -72.25K | 15.94M |
| 2017 | -11.02M | -346.70K | 9.92M |
| 2018 | -11.44M | -329.99K | 15.02M |
| 2019 | -11.69M | -24.54K | 9.02M |
| 2020 | -13.93M | -62.35K | 60.54M |
| 2021 | -22.56M | -141.36K | 1.24M |
| 2022 | -25.22M | -225.97K | 9.61M |
| 2023 | -32.37M | -864.03K | 22.93M |
CLRB Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 19.86M | 35.70M | 57.16M | 10.61M | 13.31M | 10.06M | 11.49M | 3.85M | 9.42M | 2.41M |
Operating activities | ||||||||||
Net income | -37.98M | -28.60M | -24.12M | -15.09M | -14.09M | -13.23M | -13.56M | -6.18M | -5.49M | -8.10M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 192.37K | 148.43K | 149.91K | 141.45K | 132.79K | 82.26K | 1.54M | 356.66K | 362.50K | 367.19K |
Stock-based compensation expense | 2.41M | 1.45K | 1.12M | 467.54K | 866 | 0 | 758.75K | 529.15K | 447.3K | 850.35K |
| Deferred income tax benefit | 2.41M | 1.45K | 1.12M | 467.54K | 866 | 0 | 758.75K | 529.15K | 447.3K | 850.35K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 3.70M | 1.62M | 411.71K | 780.60K | 1.12M | -258.79K | 451.32K | 740.50K | -258.06K | -228.11K |
Cash generated by operating activities | -32.37M | -25.22M | -22.56M | -13.93M | -11.69M | -11.44M | -11.02M | -8.28M | -8.21M | -8.84M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -864.03K | -225.97K | -141.36K | -62.35K | -24.54K | -384.99K | -346.70K | -72.25K | -58.47K | -29.56K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 55K | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -864.03K | -225.97K | -141.36K | -62.35K | -24.54K | -329.99K | -346.70K | -72.25K | -58.47K | -29.56K |
Financing activities | ||||||||||
Common Stock Issued | 0 | 9.61M | 34.87K | 59.71M | 9.02M | 9.07M | 4.90M | 12.32M | 3.3M | 12.39M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | -1.44M | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 8.19M | 0 | 0 | 0 | -1 |
Repayments of term debt | 0 | 0 | 0 | -184K | -2.21K | -3.03K | -89.31K | -246.07K | -122.66K | -619.19K |
Cash used in financing activities | 22.93M | 9.61M | 1.24M | 60.54M | 9.02M | 15.02M | 9.92M | 15.94M | 2.70M | 15.87M |
Net Change In Cash | -10.30M | -15.83M | -21.46M | 46.55M | -2.69M | 3.24M | -1.43M | 7.58M | -5.56M | 7.00M |
Cash at end of period | 9.56M | 19.86M | 35.70M | 57.16M | 10.61M | 13.31M | 10.06M | 11.44M | 3.85M | 9.42M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |